According to FutureWise analysis, the market for immuno-oncology in 2023 was US$ 101.4 billion and is expected to reach US$ 240 billion by 2031 at a CAGR of 12%.

Cancer immunotherapy, also known as immuno-oncology, is a way of treating cancer by employing the body's own immune system to stop, eliminate, and control the disease. By boosting your immune system, giving your body more components to boost the immunological response, and teaching your body to recognize and fight particular cancer cells, it can also aid in the elimination of cancer. In cancer immunotherapy, several therapies are available, such as targeted antibodies, cancer vaccines, adoptive cell transfer, tumor-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants. Immunotherapies are a type of biotherapy (also known as biologic therapy or biological response modifier (BRM) therapy), which uses compounds from living organisms to treat disease.

The Department of Immuno-Oncology is at the forefront of medical research that uses the body's immune system to combat cancer. Due to its potential to utilize the body's built-in immunity to infection, immunotherapy is a significant tool against cancer. T-cell treatment, which employs specialized immune system cells to target and eliminate cancer cells, and immune checkpoint blockade, which modifies or strengthens the immune system to attack and eradicate tumor cells, are two cancer immunotherapies now in use. For some people with metastatic cancer, these treatments work. But, researchers in the Department of Immuno-Oncology envision immunotherapy playing a much more significant role in the fight against cancer.

FutureWise Market Research has published a report that provides an insightful analysis of Immuno-Oncology Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Immuno-Oncology-Market/10981

Immuno-Oncology Market Segmentation:

By Product Class

• Monoclonal Antibodies
  • Naked Monoclonal Antibodies
    • Rituxan (Rituximab)
    • Avastin (Bevacizumab)
    • Herceptin (Trastuzumab)
  • Conjugated Monoclonal Antibodies
    • ADCETRIS (Brentuximab vedotin)
    • Kadcyla (Ado-trastuzumab emtansine/TDM-1)
  • Bispecific Monoclonal Antibodies
    • Blincyto (Blinatumomab)
  • Others
• Therapeutic Vaccines
  • Provenge
• Immune Checkpoint Inhibitors
  • CTLA-4 Inhibitors (Cytotoxic T-lymphocyte-associated Protein-4)
    • Yervoy (Ipilimumab)
  • PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand)
    • Opdivo (Nivolumab)
    • Keytruda (Pembrolizumab)
  • Others

By Major Indications

• Head And Neck Cancer
• Lung Cancer
• Melanoma
• Lymphoma
• Leukemia
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Immuno-Oncology Market:

• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb
• MerckCo., Inc.
• Novartis
• AstraZeneca Plc
• Pfizer Inc
• Eli Lilly and Company
• Johnson And Johnson
• Amgen Inc.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10981&license=single

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Immuno-Oncology Market By Product Class, By Major Indications and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.                                                                                                              

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

FutureWise Research

Contact Person: Vinay Thaploo.

Email: sales@futurewiseresearch.com

Contact Number: Asia: +91 8605575209 | USA: +1 3477094931

Website: www.futurewiseresearch.com